Soligenix Inc (SNGX)

2.32
0.03 1.28
OTC : Health Care
Prev Close 2.35
Open 2.28
Day Low/High 2.28 / 2.38
52 Wk Low/High 1.90 / 8.90
Volume 41.10K
Avg Volume 634.20K
Exchange OTC
Shares Outstanding 5.67M
Market Cap 13.33M
EPS -6.50
Div & Yield N.A. (N.A)

Latest News

Soligenix Receives Japanese Patent For ThermoVax® Vaccine Heat Stabilization Platform Technology

Patent describes application of ThermoVax® with RiVax®

Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results

Highlighted by Revenues of $10.4 Million

Soligenix Receives Positive Scientific Advice From The European Medicines Agency For SGX942 In The Treatment Of Oral Mucositis In Head And Neck Cancer Patients

Soligenix Receives Positive Scientific Advice From The European Medicines Agency For SGX942 In The Treatment Of Oral Mucositis In Head And Neck Cancer Patients

Follows UK Health Ministry's Granting SGX942 Promising Innovative Medicine Designation in the Treatment of Oral Mucositis

Soligenix Announces Extension Of Development Agreement With Emergent BioSolutions

Soligenix Announces Extension Of Development Agreement With Emergent BioSolutions

Supported with NIAID Contract Funding of up to $24.7 million

Soligenix Advances Collaboration With IDT Biologika

Soligenix Advances Collaboration With IDT Biologika

Supported with NIAID Contract Funding of up to $24.7 million

Soligenix And SciClone Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis

Soligenix And SciClone Establish Regional Licensing Agreement For SGX942, A Novel Product Candidate For Oral Mucositis

Agreement Includes Greater China and Other East Asia Markets

Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs

Soligenix Announces Issuance of New Composition of Matter Patent for Dusquetide Analogs

Patents provide broad protection for the innate defense regulator technology platform

Soligenix Receives Additional BARDA And NIAID Funding To Advance Development Of OrbeShield® In GI ARS

Soligenix Receives Additional BARDA And NIAID Funding To Advance Development Of OrbeShield® In GI ARS

Awarded $634,000 in additional contract funding

Soligenix Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation

Soligenix Announces Presentation Of Positive Preliminary Results Of A Heat Stable Ebola Vaccine Formulation

ThermoVax® Development Expands into Pandemic Infectious Disease